Tag:
Bavituximab
Latest Headlines
Latest Headlines
Peregrine shares spike on Ph2 cancer data
Shares of Peregrine Pharmaceuticals ( $PPHM ) spiked 20% this morning after the company reported that advanced and metastatic breast cancer patients taking a combination of bavituximab and docetaxel
Peregrine posts promising data on Phase II lung cancer trial
Shares of Peregrine Pharmaceuticals ( PPHM ) shot up 14 percent after the biotech reported that its monoclonal antibody bavituximab in combination with chemo significantly improved the
Peregrine touts data for breast cancer
Tustin, CA-based Peregrine Pharmaceuticals says its lead program, bavituximab, has hit its primary endpoint in a Phase II study for advanced breast cancer. Fourteen of the 15 patients enrolled in
